Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo
Open Access
- 12 April 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 8 (2), R21
- https://doi.org/10.1186/bcr1395
Abstract
The ras pathway is essential for cell growth and proliferation. The effects of R115777, a farnesyl transferase inhibitor, were investigated in cancer cell lines expressing varying levels of growth factor receptors and with differing ras status. Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested. In vitro, the concentrations required to reduce cell numbers by 50% (50% inhibitory concentration) were established (MDA-MB231, MCF-7, MCF-7/HER2-18, BT-474, SK-BR3 and SKOV3). Human DCIS was implanted in nude mice or, in separate experiments, cultured cells were injected (MDA-MB231, MCF-7/HER2-18, SKOV3) and allowed to form tumours. Proliferation and apoptosis were determined by immunohistochemistry in xenografts and cell tumours. The 50% inhibitory concentrations varied a hundred-fold, from 39 nmol/l (± 26 nmol/l) for SKBR3 to 5.9 μmol/l(± 0.8 μmol/l) for MDA-MB231. In MCF-7/HER2-18 and SKOV3 cells the levels of tumour growth inhibition were approximately 85% and 40%, respectively. There was a significant decrease in the cell turnover index (CTI; proliferation/apoptosis). In MDA-MB 231 with activated k-ras no inhibition was observed. In treated DCIS xenografts proliferation decreased and apoptosis increased. The CTI ratio between the start and 1 and 2 weeks of treatment were 1.99 and 1.50, respectively, for controls and 0.85 (P = 0.005) and 0.75 (P = 0.08) for treated xenografts. Treatment with the farnesyl transferase inhibitor reduced cell growth in vitro and cell tumour growth in vivo. In DCIS treatment resulted in a reduced CTI. R115777 is a promising treatment for breast cancer but the relation between effect and growth factor receptor and ras status has to be established.Keywords
This publication has 45 references indexed in Scilit:
- Development of Farnesyl Transferase Inhibitors: A ReviewThe Oncologist, 2005
- Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2004
- Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast CancerJournal of Clinical Oncology, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- A Formalin-Fixed, Paraffin-Processed Cell Line Standard for Quality Control of Immunohistochemical Assay of HER-2/neu Expression in Breast CancerAmerican Journal of Clinical Pathology, 2002
- Tumour markers in breast carcinoma correlate with grade rather than with invasivenessBritish Journal of Cancer, 2001
- Differential Expression and Mutation of therasFamily Genes in Human Breast CancerBiochemical and Biophysical Research Communications, 1998
- Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: detected by terminal‐deoxynucleotidyl‐transferase‐mediated dUTP‐FITC nick end labelling (TUNEL)Histopathology, 1997
- Aberrant function of the Ras signal transduction pathway in human breast cancerBreast Cancer Research and Treatment, 1995
- Neu-Protein Overexpression in Breast CancerThe New England Journal of Medicine, 1988